Literature DB >> 30117269

Triaryl Pyrazole Toll-Like Receptor Signaling Inhibitors: Structure-Activity Relationships Governing Pan- and Selective Signaling Inhibitors.

Julie A Pollock1,2, Naina Sharma1, Sirish K Ippagunta3,4, Vanessa Redecke3, Hans Häcker3, John A Katzenellenbogen1.   

Abstract

The immune system uses members of the toll-like receptor (TLR) family to recognize a variety of pathogen- and host-derived molecules in order to initiate immune responses. Although TLR-mediated, pro-inflammatory immune responses are essential for host defense, prolonged and exaggerated activation can result in inflammation pathology that manifests in a variety of diseases. Therefore, small-molecule inhibitors of the TLR signaling pathway might have promise as anti-inflammatory drugs. We previously identified a class of triaryl pyrazole compounds that inhibit TLR signaling by modulation of the protein-protein interactions essential to the pathway. We have now systematically examined the structural features essential for inhibition of this pathway, revealing characteristics of compounds that inhibited all TLRs tested (pan-TLR signaling inhibitors) as well as compounds that selectively inhibited certain TLRs. These findings reveal interesting classes of compounds that could be optimized for particular inflammatory diseases governed by different TLRs.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  drug design; heterocycles; immune response; structure-activity relationships; toll-like receptor signaling

Mesh:

Substances:

Year:  2018        PMID: 30117269      PMCID: PMC7134392          DOI: 10.1002/cmdc.201800417

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  25 in total

1.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

Authors:  Susan L McGovern; Emilia Caselli; Nikolaus Grigorieff; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

Review 2.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

3.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

4.  Importance of Toll-like receptor 2 in mitochondrial dysfunction during polymicrobial sepsis.

Authors:  Yu Gong; Lin Zou; Yan Feng; Dan Li; Jiayan Cai; Dunjin Chen; Wei Chao
Journal:  Anesthesiology       Date:  2014-12       Impact factor: 7.892

Review 5.  Update on the role of Toll-like receptors during bacterial infections and sepsis.

Authors:  Sylvia Knapp
Journal:  Wien Med Wochenschr       Date:  2010-03

6.  Triarylpyrazoles with basic side chains: development of pyrazole-based estrogen receptor antagonists.

Authors:  S R Stauffer; Y R Huang; Z D Aron; C J Coletta; J Sun; B S Katzenellenbogen; J A Katzenellenbogen
Journal:  Bioorg Med Chem       Date:  2001-01       Impact factor: 3.641

7.  Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock.

Authors:  Thomas Vogl; Klaus Tenbrock; Stephan Ludwig; Nadja Leukert; Christina Ehrhardt; Marieke A D van Zoelen; Wolfgang Nacken; Dirk Foell; Tom van der Poll; Clemens Sorg; Johannes Roth
Journal:  Nat Med       Date:  2007-09-02       Impact factor: 53.440

8.  Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury.

Authors:  Zubin M Bamboat; Vinod P Balachandran; Lee M Ocuin; Hebroon Obaid; George Plitas; Ronald P DeMatteo
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

9.  Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice.

Authors:  Marie-Laure Santiago-Raber; Isabelle Dunand-Sauthier; Tianfu Wu; Quan-Zhen Li; Satoshi Uematsu; Shizuo Akira; Walter Reith; Chandra Mohan; Brian L Kotzin; Shozo Izui
Journal:  J Autoimmun       Date:  2009-11-26       Impact factor: 7.094

10.  Critical role of TLR9 in acute graft-versus-host disease.

Authors:  Claudia Calcaterra; Lucia Sfondrini; Anna Rossini; Michele Sommariva; Cristiano Rumio; Sylvie Ménard; Andrea Balsari
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

View more
  1 in total

1.  Select targeting of intracellular Toll-interleukin-1 receptor resistance domains for protection against influenza-induced disease.

Authors:  Kari Ann Shirey; Wendy Lai; Lindsey J Brown; Jorge C G Blanco; Robert Beadenkopf; Yajing Wang; Stefanie N Vogel; Greg A Snyder
Journal:  Innate Immun       Date:  2020-01       Impact factor: 2.680

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.